PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Cancers0 citationsOpen Access

Racial and Ethnic Disparities in Second Primary Lung Cancer After Breast Radiotherapy: A SEER Cohort Analysis (2000–2022)

FQFares A. QtaishatMHMohammad HamadAMAya Musa

Key Points

  • The study aims to examine racial and ethnic disparities in second primary lung cancer risk and survival among breast cancer survivors treated with radiotherapy.
  • Analyzed data from SEER-17 (2000–2022) of breast cancer patients receiving radiotherapy.
  • Excluded patients who died within two months post-treatment.
  • Calculated standardized incidence ratios (SIRs) by race, ethnicity, and marital status.
  • Assessed five-year overall survival (OS) rates after SPLC and mean age at death.
  • Out of 558,493 patients, 6,674 developed SPLC, indicating an incidence of 1.19%.
  • AI/AN patients had the highest SPLC risk (SIR 1.82), while White survivors showed no increase (SIR 0.96).
  • Married individuals had a 12% lower incidence of SPLC (SIR 0.88).
  • Five-year survival after SPLC was 28.0%, with API (32.2%) and AI/AN (32.5%) patients showing the highest survival rates.

Abstract

Background: Adjuvant radiation therapy for breast cancer improves survival but may expose thoracic organs to low-dose radiation, increasing the risk of second primary lung cancer (SPLC). Racial and ethnic disparities and social factors influencing SPLC risk remain underexplored. Objectives: We quantified racial and ethnic differences in SPLC incidence and survival among radiotherapy-treated breast cancer survivors and assessed the potential protective role of marital status. Methods: Using SEER-17 (2000–2022), we identified patients with first primary breast cancer receiving radiotherapy, excluding those who died within two months. Standardized incidence ratios (SIRs) assessed observed versus expected SPLC cases by race and ethnicity and marital status, and five-year overall survival (OS) after SPLC and mean age at death were calculated. Racial categories included White, Black, Asian or Pacific Islander (API), and American Indian or Alaska Native (AI/AN); ethnicity was categorized as Hispanic or non-Hispanic. Results: Among 558,493 patients, 6674 developed SPLC (1.19%). Risk varied significantly by race (p < 0.05). AI/AN patients had the highest overall risk (SIR 1.82), particularly 12–59 months and ≥120 months post-treatment. Black (SIR 1.21) and API (SIR 1.23) survivors had sustained elevated risk, while White survivors showed no overall increase (SIR 0.96) and Hispanic survivors had lower risk (SIR 0.72). Married individuals had 12% lower SPLC incidence (SIR 0.88). Five-year overall survival after SPLC was 28.0%, with significant variation by race and ethnicity (p = 0.002). API (32.2%) and AI/AN (32.5%) patients had the highest survival, followed by White (28.0%) and Black patients (25.6%). Married patients had higher five-year survival (31.8% vs. 25.0%) and older mean age at death (64.3 vs. 48.6 years) compared to unmarried patients. Conclusions: SPLC risk and prognosis after breast radiotherapy differ by race, ethnicity, and marital status. These findings highlight the importance of context-aware survivorship counseling and support the consideration of personalized lung cancer screening for breast cancer survivors.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Qtaishat et al. (2026) studied this question.

synapsesocial.com/papers/6996a7efecb39a600b3ee1e4https://doi.org/10.3390/cancers18040635
Ask AI
Helpful
Bookmark
Share
View Full Paper